原发性肝癌患者TACE术前后血清GP73水平变化及临床价值

Abstract
Figure/Table
References (22)
Related Citation (15)

Download: PDF (965 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical significance of changes of serum Golgi protein 73 (GP73) level in patients with primary hepatocellular carcinoma (PHC) undergoing transcatheter arterial chemoembolization (TACE) before and after operation, so as to understand whether GP73 can be used as an evaluation index of TACE efficacy. Methods A total of 88 patients with PHC concurrent TACE in the First People′s Hospital of Ziyang, Sichuan Province from September 2016 to October 2018 were enrolled and divided into the improvement group (39 cases) and the deterioration group (49 cases) according to the treatment effect of TACE. The changes of GP73, alpha-fetal protein (AFP) and liver function before and after TACE were recorded. Results The serum GP73 level in the improvement group decreased 1 week after operation compared with that before operation, with statistically significant difference (P ＜ 0.05). Compared with those before and 1 week after the operation, serum GP73 level in the improvement group decreased 1 month after operation, with statistically significant difference (P ＜ 0.05). Compared with that before operation, serum GP73 level in the deterioration group increased 1 week and 1 month after operation, and 1 month after operation was higher than 1 week after operation, with statistically significant differences (all P ＜ 0.05). Serum GP73 level in the improvement group was lower than that in the deterioration group 1 week and 1 month after operation, and the differences were statistically significant (all P ＜ 0.05). One week before TACE, serum GP73 level was not correlated with AFP (rs = 0.056, 0.192, P = 0.613,0.077). Serum GP73 was positively correlated with total bilirubin (rs = 0.295, P = 0.006), and positively correlated with alanine transaminase (rs = 0.301, P = 0.005). Conclusion GP73 may be an effective indicator for evaluating the efficacy of TACE in PHC patients before and after operation, and can reflect the liver function of PHC patients. Effectiveness of GP73 in efficacy monitoring in patients with AFP negative needs to be further expanded to draw conclusions.

Key words： Primary hepatocellular carcinoma Golgi protein 73 Transcatheter arterial chemoembolization

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Li XIAO Wei CHEN Kuangrong ZHANG Huiling LI Hui DENG Licong ZHANG Hongwei

Cite this article:

ZHANG Li XIAO Wei CHEN Kuangrong ZHANG Huiling LI Hui DENG Licong ZHANG Hongwei. Changes of serum GP73 level in patients with primary hepatocellular carcinoma before and after TACE and its clinical value[J]. 中国医药导报, 2020, 17(20): 127-130,139.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I20/127

[1] Torre LA，Bray F，Siegel RL，et al. Global cancer statistics，2012 [J]. CA Cancer J Clin，2015，65（2）：87-108.
[2] Chen W，Zheng R，Baade PD，et al. Cancer statistics in China，2015 [J]. CA Cancer J Clin，2016，66（2）：115-132.
[3] Dhir M，Melin AA，Douaiher J，et al. A Review and Update of Treatment Options nd Controversies in the Management of Hepatocellular Carcinoma [J]. Ann Surg，2016，236（6）：1112-1125.
[4] 中华人民共和国卫生和计划生育委员会医政医管局.原发性肝癌诊疗规范（2017年版）[J].中华消化外科杂志，2017，16（7）：635-647.
[5] 李虎子，贾英杰，孔凡铭，等.改良RECIST标准更适用经TACE治疗的肝癌患者的预后评价[J].介入放射学杂志，2016，25（1）：29-33.
[6] Child-Pugh肝功能改良分级法[J].中华普通外科学文献：电子版，2013，（2）：153.
[7] Chen Y，Yue X，Fujita H，et al. Three-way decision support for diagnosis on focal liver lesions [J]. Knowl-based Syst，2017，127：85-99.
[8] 赵睿.联合检测AFP-L3和GP73在原发性肝癌中的诊断价值及影响原发性肝癌患者TACE预后因素分析[D].蚌埠：蚌埠医学院，2013.
[9] Xia Y，Zhang Y，Shen M，et al. Golgi protein 73 and its diagnostic value in liver diseases [J]. Cell Prolif，2019，52（2）：e12538.
[10] Iftikhar R，Kladney RD，Havlioglu N，et al. Disease- and cell-specific expression of GP73 in human liver disease [J]. Am J Gastroenterol，2004，99（6）：1087-1095.
[11] Xu Z，Liu L，Pan X，et al. Serum Golgi Protein 73（GP73）is a Diagnostic and Prognostic Marker of Chronic HBV Liver Disease [J]. Medicine （Baltimore），2015，94（12）：e659.
[12] 赵睿，王启之，郑海伦.原发性肝癌患者TACE前后血清GP73的变化及意义[J].中华全科医学，2018，16（10）： 1623-1625.
[13] 马铭，谢明瑞.新肝癌血清标记物GP73在肝癌介入治疗前后的变化及预后的关系[J].实用癌症杂志，2018， 33（11）：1756-1758，1762.
[14] Liu Y，Zhang X，Zhou S，et al. Knockdown of Golgi phosphoprotein 73 blocks the trafficking of matrix metalloproteinase-2 in hepatocellular carcinoma cells and inhibits cell invasion [J]. J Cell Mol Med，2019，23（4）：2399-2409.
[15] 侯旭.肿瘤抑制轴MicroRNA-141-3p/GP73通过调节上皮-间质转化抑制肝癌细胞的生长及转移[D].济南：山东大学，2018：1-172.
[16] Kladney RD，Cui X，Bulla GA，et al. Expression of GP73，a resident Golgi membrane protein，in viral and nonviral liver disease [J]. Hepatology，2002，35（6）：1431-1440.
[17] Wang F，Long Q，Gong Y，et al. Epithelium-Specific ETS （ESE）-1 upregulated GP73 expression in hepatocellular carcinoma cells [J]. Cell Biosci，2014，4（1）：76.
[18] Wei M，Xu Z，Pan X，et al. Serum GP73 - An Additional Biochemical Marker for Liver Inflammation in Chronic HBV Infected Patients with Normal or Slightly Raised ALT [J]. Sci Rep，2019，9（1）：1170.
[19] 孙景武，刘志春，张雷，等.原发性肝细胞癌与胆管细胞癌中高尔基体蛋白73及甲胎蛋白表达的临床意义[J].实用癌症杂志，2019，34（5）：737-742.
[20] 王清睿，胡赤丁，吴琳，等.原发性肝细胞癌切除术后复发的危险因素分析[J].疑难病杂志，2018，17（7）：706-709.
[21] 鲁磊，叶新平.手术切除联合术后肝动脉化疗栓塞术治疗原发性肝细胞癌的临床效果[J].中国医药，2016，11（12）：1790-1794.
[22] 王媛媛，朱丽影，钟丽华，等.原发性肝癌患者TACE前后血清GP73动态变化[J].中国肝脏病杂志：电子版，2013（2）：14-18.